Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.
- 18 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.